Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC Congress 2025 Releases its Late-Breaking Scientific Programme
Added: 10 months ago Source:  ESC Congress 2025 Scientific Programme
ESC Congress 2025 has released twenty-eight late-breaking trials and science sessions to be presented in August 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Late-Breaking Clinical Science: Inflammation and Immune Biomarkers in Cardiovascular Risk PredictionFriday 29th August, 08:15am – 09:45am (CEST… View more

Imaging & Diagnostics

Intervention
Diagnostic Red Flags are Common in Hypertrophic Cardiomyopathy, Study Finds
Added: 9 months ago Source:  Radcliffe Cardiology
According to European Society of Cardiology (ESC) guidelines, a systematic search for diagnostic clues, or ‘red flags’ (RFs), is recommended in patients with hypertrophic cardiomyopathy (HCM) to help tailor disease management. A new study published in the European Heart Journal has investigated the prevalence and clinical significance of these RFs across different HCM phenotypes and clinical… View more

Imaging & Diagnostics

Inherited and Congenital Cardiac Conditions
Aficamten Superior to Metoprolol in oHCM: MAPLE-HCM
Added: 2 months ago Source:  CFR Journal Radcliffe Cardiology
A prespecified, secondary analysis of the MAPLE-HCM trial has shown that aficamten monotherapy provides superior and rapid benefits across multiple domains of disease burden compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).¹ Aficamten is a next-in-class cardiac myosin inhibitor (CMI) designed to reduce myocardial hypercontractility by decreasing… View more

Heart Failure
AI Screening Improves ATTR-CM Diagnosis Rates
Added: 6 months ago Source:  Radcliffe Cardiology
An artificial intelligence (AI)-augmented clinical programme may significantly improve the detection of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is frequently underdiagnosed, according to the results of a new nonrandomized clinical trial.¹ The study evaluated an AI model, ATTRACTnet, in a real-world setting to identify patients missed by usual care.The ATTRACTnet model was… View more

Imaging & Diagnostics

Digital Health
ICOS-CORE Whitepaper Calls for Rigorous Evidence to Support Cardio-oncology Rehabilitation
Added: 9 months ago Source:  Radcliffe Cardiology
A new whitepaper from the International Cardio-Oncology Society (ICOS) CORE working group outlines a critical roadmap for advancing the cardiovascular care of cancer survivors. Published in the European Heart Journal, the paper reviews the current evidence for cardio-oncology rehabilitation and exercise (CORE) programmes and sets new standards for future research to address significant knowledge… View more

Prevention & Chronic Conditions

CV Disease in Special Populations
Smartwatch Data Predicts Heart Failure Exacerbations
Added: 1 month ago Source:  CFR Journal
Consumer wearable devices may offer a scalable method for the daily monitoring of heart failure (HF) symptoms and predicting exacerbations. A new study has detailed how a deep learning model using Apple Watch data can estimate cardiopulmonary fitness and provide early risk discrimination for unplanned healthcare events in patients with HF.¹MethodologyThe Ted Rogers Understanding Exacerbations of… View more

Digital Health

Heart Failure
Aficamten Effective in Mildly Symptomatic oHCM Patients
Added: 7 months ago Source:  Radcliffe Cardiology
New data from the SEQUOIA-HCM trial suggests that the cardiac myosin inhibitor aficamten provides significant clinical benefits for patients with obstructive hypertrophic cardiomyopathy (oHCM) and mild symptoms, with an efficacy and safety profile comparable to that seen in patients with more advanced symptoms.¹Aficamten is a novel, selective cardiac myosin inhibitor that works by reducing the… View more

Inherited and Congenital Cardiac Conditions

Heart Failure
Increasing VA-ECMO Flow Does Not Typically Raise Pulmonary Capillary Wedge Pressure in Cardiogenic Shock
Added: 8 months ago Source:  Radcliffe Cardiology
New research challenges the common assumption that high flow rates during venoarterial extracorporeal membrane oxygenation (VA-ECMO) increase pulmonary capillary wedge pressure (PCWP) and the risk of pulmonary oedema in patients with cardiogenic shock. The ECMO-Flow trial found that increasing VA-ECMO flow often has a neutral or even beneficial effect on PCWP, despite raising left ventricular… View more

Imaging & Diagnostics

Heart Failure
Undiagnosed Sleep Apnoea Linked to Adverse Myocardial Remodelling in Hypertrophic Cardiomyopathy
Added: 8 months ago Source:  Radcliffe Cardiology
Sleep-disordered breathing (SDB), a condition mediated by intermittent hypoxaemia and autonomic dysregulation, is a well-established contributor to cardiovascular morbidity. A new prospective cohort study suggests that patients with hypertrophic cardiomyopathy (HCM) are particularly at risk, revealing a high prevalence of previously undiagnosed SDB in this population. The research links the… View more

Imaging & Diagnostics

Heart Failure
Mavacamten Fails to Meet Primary Endpoints in Non-obstructive Hypertrophic Cardiomyopathy
Added: 8 months ago Source:  Radcliffe Cardiology
The ODYSSEY-HCM trial, evaluating the cardiac myosin inhibitor mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (HCM), did not meet its dual primary endpoints for improving functional capacity or patient-reported symptoms.¹ The findings were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the New England… View more

Guidelines & Statements

Heart Failure